UPDATE: Cantor Fitzgerald Assumes Cerus (CERS) at Overweight

(updating comment)

Cantor Fitzgerald analyst Brandon Folkes assumes coverage on Cerus (NASDAQ: CERS) with a Overweight rating and a price target of $9.00.

The analyst comments "CERS is the company in our assumption universe that we believe is likely to be the largest beneficiary of a post COVID-19 world as we believe there will be a continue emphasis on ensuring a reduction of the risk of transfusion transmitted bacterial pathogens, and we believe INTERCEPT offers significant advantages over its competitors in reducing a wide range of pathogens."

For an analyst ratings summary and ratings history on Cerus click here. For more ratings news on Cerus click here.

Shares of Cerus closed at $6.04 yesterday.

You May Also Be Interested In

• Goldman Sachs Starts Scribe Therapeutics Inc (SCTX) at Early-Stage Biotech
• RBC Capital Downgrades EyePoint Inc. (EYPT) to Sector Perform
• RBC Capital Downgrades Hermes International (RMS:FP) (HESAY) to Sector Perform